CTSC
Dipeptidyl peptidase 1
As of the edition of 20 October 2026, CTSC (dipeptidyl peptidase 1, UniProt P53634) has 3 drugs tested at it and 5 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P53634
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 18
- Disease areas
- Lungs and airways; Digestive system; Infections; Inherited and neonatal; Immune system; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 41
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Brensocatib | Marketed | Phase 3 | Ends 2035 |
| BI 1291583 | Active | Phase 3 | none listed |
| HSK31858 | Active | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Insmed | Route B |
The other 4 companies at CTSC
In the product5 companies in all; 4 are not named here, and no score is.
See the 5 companies at CTSC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.